Previous Close | 6.15 |
Open | 5.90 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 120.00 |
Expire Date | 2024-06-21 |
Day's Range | 5.90 - 6.98 |
Contract Range | N/A |
Volume | |
Open Interest | 3.43k |
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these ...
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
RAHWAY, N.J., May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. The FDA has set a Prescription Drug User Fee